Anti-Inflammatory Agents
Chemokine CCL17
/ metabolism
Chemokine CCL22
/ metabolism
Dermatitis, Atopic
/ drug therapy
Down-Regulation
/ drug effects
Extracellular Signal-Regulated MAP Kinases
/ metabolism
HaCaT Cells
Humans
Inflammation Mediators
/ metabolism
Interferon-gamma
/ adverse effects
NF-kappa B
/ metabolism
Phytotherapy
Plant Extracts
/ isolation & purification
Porphyra
/ chemistry
Tumor Necrosis Factor-alpha
/ adverse effects
Xanthophylls
/ isolation & purification
p38 Mitogen-Activated Protein Kinases
/ metabolism
AD
MDC
NF-κB
Pyropia yezoensis
TARC
astaxanthin
mitogen-activated protein kinases
xanthophyll
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
27 Apr 2020
27 Apr 2020
Historique:
received:
30
03
2020
revised:
22
04
2020
accepted:
25
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Pyropia yezoensis, a red alga, is popular and harvested a lot in East Asia and is famous for its medicinal properties attributable to its bioactive compounds including amino acids (porphyra-334 and shinorine, etc.), polysaccharides, phytosterols, and pigments, but its anti-inflammatory effect and mechanism of anti-atopic dermatitis (AD) have not been elucidated. In this study, we investigate the anti-AD effect of P. yezoensis extract (PYE) on mRNA and protein levels of the pro-inflammatory chemokines, thymus, and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), in human HaCaT keratinocyte cells treated to interferon (IFN)-γ or tumor necrosis factor (TNF)-α (10 ng/mL each). The effect of the PYE on extracellular signal-regulated kinase (ERK) and other mitogen-activated protein kinases (MAPKs) was related to its suppression of TARC and MDC production by blocking NF-κB activation in HaCaT cells. Furthermore, astaxanthin and xanthophyll from P. yezoensis were identified as anti-AD candidate compounds. These results suggest that the PYE may improve AD and contained two carotenoids by regulating pro-inflammatory chemokines.
Identifiants
pubmed: 32349358
pii: nu12051238
doi: 10.3390/nu12051238
pmc: PMC7285056
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Chemokine CCL17
0
Chemokine CCL22
0
Inflammation Mediators
0
NF-kappa B
0
Plant Extracts
0
Tumor Necrosis Factor-alpha
0
Xanthophylls
0
Interferon-gamma
82115-62-6
astaxanthine
8XPW32PR7I
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2017R1A6A1A06015181
Organisme : Incheon National University
ID : Incheon National University Research Grant in 2017
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Int J Biol Macromol. 2015 Mar;74:68-75
pubmed: 25499893
Cancer Lett. 2004 Aug 20;212(1):15-20
pubmed: 15246557
Mol Med Rep. 2015 May;11(5):3914-9
pubmed: 25626067
J Dermatol Sci. 2006 Aug;43(2):75-84
pubmed: 16859899
Phytother Res. 2008 Sep;22(9):1149-53
pubmed: 18729249
Int J Mol Med. 2011 Nov;28(5):809-15
pubmed: 21701768
Trop Anim Health Prod. 2019 Jun;51(5):1125-1134
pubmed: 30612290
J Immunol. 2000 Jul 15;165(2):1013-21
pubmed: 10878378
Biomol Ther (Seoul). 2015 May;23(3):238-44
pubmed: 25995822
Regul Toxicol Pharmacol. 2007 Nov;49(2):101-6
pubmed: 17869397
Int Immunopharmacol. 2015 Dec;29(2):401-407
pubmed: 26507164
Chem Pharm Bull (Tokyo). 2013;61(10):1002-8
pubmed: 24088692
Gut. 2003 Jan;52(1):144-51
pubmed: 12477778
Int J Food Sci Nutr. 2009;60 Suppl 2:46-56
pubmed: 19212859
J Biol Chem. 2004 Jun 18;279(25):26287-99
pubmed: 15090542
J Dermatol Sci. 2006 Nov;44(2):93-9
pubmed: 17008059
Physiol Rev. 2001 Apr;81(2):807-69
pubmed: 11274345
Science. 2002 Dec 6;298(5600):1911-2
pubmed: 12471242
J Immunol. 2005 Aug 15;175(4):2721-9
pubmed: 16081850
Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453-60
pubmed: 26226355
Biochem Biophys Res Commun. 2012 Jan 27;417(4):1254-9
pubmed: 22227193
Life Sci. 2006 Oct 12;79(20):1956-62
pubmed: 16876203
Biomed Pharmacother. 2017 Jun;90:437-445
pubmed: 28391165
J Dermatol Sci. 2003 Apr;31(2):111-7
pubmed: 12670721
Nutr Metab (Lond). 2010 Mar 05;7:18
pubmed: 20205737
J Allergy Clin Immunol. 2001 May;107(5):871-7
pubmed: 11344355
J Biochem. 2012 Jan;151(1):65-74
pubmed: 21976706
Int Immunopharmacol. 2020 Feb 20;82:106146
pubmed: 32088638
Mol Immunol. 2009 Jun;46(10):1925-34
pubmed: 19371952
Front Pharmacol. 2019 Aug 28;10:906
pubmed: 31555126
J Ethnopharmacol. 2012 Oct 31;144(1):182-9
pubmed: 22974545
Physiol Behav. 2019 Nov 1;211:112650
pubmed: 31425700
Biochem Biophys Res Commun. 2009 Sep 11;387(1):115-20
pubmed: 19576177
Arch Pharm Res. 2010 Nov;33(11):1867-76
pubmed: 21116791
Int Immunopharmacol. 2016 Nov;40:458-465
pubmed: 27728897
Food Chem Toxicol. 2014 Jun;68:135-41
pubmed: 24675422
Nature. 1994 Dec 22-29;372(6508):739-46
pubmed: 7997261
Molecules. 2016 Jun 22;21(6):
pubmed: 27338335
Int J Biol Macromol. 2014 Jul;68:48-9
pubmed: 24736124
Int J Mol Med. 2016 Aug;38(2):482-90
pubmed: 27314211
Int J Mol Med. 2014 Sep;34(3):796-803
pubmed: 24946848
J Allergy Clin Immunol. 2000 May;105(5):860-76
pubmed: 10808164
J Clin Invest. 1999 Oct;104(8):1097-105
pubmed: 10525048
Mar Drugs. 2019 Feb 18;17(2):
pubmed: 30781690
Physiol Rev. 1999 Jan;79(1):143-80
pubmed: 9922370
Evid Based Complement Alternat Med. 2012;2012:617494
pubmed: 21785648
Mar Drugs. 2018 Nov 01;16(11):
pubmed: 30388860